Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt
Dec 1, 2025 · 3085
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a …
Comments
Join the discussion about this podcast.
No comments yet. Be the first to share your thoughts.
Comments are only available to logged-in users. Log in or create an account to join the discussion.